SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at Tvardi Therapeutics, Inc. following a significant drop in its stock price due to disappointing clinical trial results [2][3]. Company Overview - Tvardi Therapeutics, Inc. is a biopharmaceutical company whose shares fell over 80% after the release of preliminary data from the Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis [2][3]. Clinical Trial Results - The Phase 2 REVERT clinical trial aimed to evaluate safety, pharmacokinetics, and exploratory outcomes related to lung function, but the preliminary data indicated that the study did not meet its goals [3]. - The data showed that patients' baseline characteristics were similar across treatment arms, except for the percent predicted Forced Vital Capacity (FVC), which was lower in the placebo group compared to the TTI-101 group [3].